<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03443037</url>
  </required_header>
  <id_info>
    <org_study_id>265-SBKAEK</org_study_id>
    <nct_id>NCT03443037</nct_id>
  </id_info>
  <brief_title>Benefits of Amantadine in Patients With Coma State</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dokuz Eylul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dokuz Eylul University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was a single center observational-prospective study and approved by local ethics&#xD;
      committee. Patients in coma state due to traumatic brain injury, cardiac arrest or ischemic&#xD;
      stroke who are older than 18 years of age were included in the study. Patients who received&#xD;
      amantadine 200mg/day for fourteen days according to ICU protocols decided by primary&#xD;
      physician formed the amantadine group, and the rest of the subjects were included in the&#xD;
      control group. All patients were evaluated for Glasgow Coma Score, JFK Coma Recovery Scale&#xD;
      and Disability Rating Scale once a week for three months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glascow Coma Score</measure>
    <time_frame>1. At the time of enrollment 2. 12 weeks after the enrollment</time_frame>
    <description>Glascow Coma Score</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Coma; Prolonged</condition>
  <condition>Amantadine</condition>
  <arm_group>
    <arm_group_label>Amantadine group</arm_group_label>
    <description>Patients admitted to the critical care with diagnosis of coma state who have received amantadin 200 mg / day for fourteen days according to İCU protocols decided by primary physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients admitted to the critical care with diagnosis of coma state who haven't received amantadin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amantadine sulphate</intervention_name>
    <arm_group_label>Amantadine group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with the coma state duo to ischemic stroke, brain hemorhage, anoxic brain damage&#xD;
        included in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years, ≤ 65 years&#xD;
&#xD;
          -  GCS score ≤ 8&#xD;
&#xD;
          -  Coma state due to ischemic stroke, brain hemorhage, anoxic brain damage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 years, &gt; 65 years&#xD;
&#xD;
          -  Patients admitted to the critical care without diagnosis of coma state&#xD;
&#xD;
          -  Patients admitted to critical care with coma state that are not duo to ischemic&#xD;
             stroke, brain hemorhage, anoxic brain damage&#xD;
&#xD;
          -  Metastatic malignant neoplazm&#xD;
&#xD;
          -  Congenital or acquired brain function problem (cerebral palsy, autism etc)&#xD;
&#xD;
          -  Patients with amantadine allergy&#xD;
&#xD;
          -  Progressive degenerative diseases (Alzheimer, Parkinson diseases etc)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Necati Gokmen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dokuz Eylul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kutlay Aydin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dokuz Eylul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kutlay Aydin</last_name>
    <role>Study Director</role>
    <affiliation>Dokuz Eylul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Begum Ergan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dokuz Eylul University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kutlay Aydin, MD</last_name>
    <phone>+905322649294</phone>
    <email>kutlayaydin@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dokuz Eylul University</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kutlay Aydin, MD</last_name>
      <phone>+905322649294</phone>
      <email>kutlayaydin@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zehra Mermi, MD</last_name>
      <phone>+905331680832</phone>
      <email>zehramermi@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>September 5, 2018</last_update_submitted>
  <last_update_submitted_qc>September 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dokuz Eylul University</investigator_affiliation>
    <investigator_full_name>Begum Ergan</investigator_full_name>
    <investigator_title>Staff in the department of pulmonary and critical care medicine</investigator_title>
  </responsible_party>
  <keyword>Coma</keyword>
  <keyword>Disability</keyword>
  <keyword>amantadine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

